Skip to content

Effects of plant extracts on appetite, energy intake and the glycemic response to a carbohydrate meal

Activation of the ileal brake- A nutritional intervention study to assess the efficacy of a starch breakdown inhibitor and a glucose uptake inhibitor present in natural plant extracts, on the oral delivery of carbohydrates, in modulating postprandial glucose, appetite and food intake in healthy and non-obese males.

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12614001084673
Enrollment
20
Registered
2014-10-10
Start date
2014-10-13
Completion date
2014-12-01
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The gastrointestinal (GI) tract and specifically the most distal part of the small intestine (SI), the ileum, has become a renewed focus of interest for mechanisms targeting appetite suppression. The ‘ileal brake’ is stimulated when energy-containing nutrients are delivered beyond the duodenum and jejunum and into the ileum, and is named for the feedback loop which slows or ‘brakes’ gastric emptying and duodenojejunal motility. More recently it has been hypothesised that the ileal brake also promotes secretion of satiety-enhancing GI peptides and suppresses hunger, and hence in turn places a ’brake’ on food intake. Postprandial delivery of macronutrients to the ileum, other than unavailable carbohydrates (CHO) which bypass absorption in the small intestine en route to fermentation in the large bowel, is an uncommon event and hence this brake mechanism is rarely activated following a meal. Evidence linking the ileal brake to enhanced satiety can be found from a number of studies that have delivered nutrients to the ileum enterally. Early nasoileal (NI) tube feeding studies where lipid emulsions were infused directly into the ileum significantly decreased appetite and food intake (Welch et al., 1985; Welch et al., 1988b; Welch et al., 1988c; Maljaars et al., 2008, 20009, 2010, 2011, 2012; see review by Shin et al., 2013). There is some preliminary evidence that commercial lipid formulations designed to resist digestion and absorption in the proximal small intestine are transported to the ileum and suppress food intake (Burns et al., 2000, 2001, 2002; Diepvens et al., 2007), although findings from these feeding studies remain mixed (Smit et al., 2011; Chan et al., 2012). Our research group has recently shown that hunger and food intake can be altered acutely by infusion of glucose in to the ileum using an NI tube (Shin et al., unpublished data) suggesting that carbohydrates can also activate the ileal brake mechanism. However, no corresponding evidence exists for ileal brake activation following the ingestion of carbohydrate containing foods. This is likely to be due to the very efficient digestion and absorption of carbohydrates by the proximal SI resulting in minimal glucose availability in the ileum. In order to ensure arrival of CHOs into the distal small intestine (ileum) it is necessary to induce a degree of carbohydrate malabsorption in the proximal small intestine (duodenum and jejunum). This approach has previously been demonstrated using a carbohydrate meal and pharmacological interventions such as the a-glucosidase inhibitor migitol (Lee et al., 2002; Kaku et al., 2012) or a novel glucose transport inhibitor LX4211 (Zambrowicz et al., 2013) where enhanced ratings of satiety and postprandial GLP-1 and PYY concentrations beyond 2 h have been demonstrated, indicating ileal brake activation. A number of natural occurring plant phytochemicals have been demonstrated to posses similar carbohydrate malabsorption potential (Lakshimi et al., 2012), although their ability to trigger ileal brake activation has not as yet been demonstrated in vivo. We have recently identified in vitro, a commercially available grape seed extract (Oxifend, Registerd Trademark, grape seed extract, New Zealand Extracts Ltd) and food-grade onion skin extract OSE produced on a pilot scale in collaboration with the Food Processing Engineering Lab in Tamaki Campus, University of Auckland, using a proprietary freeze-drying method, possessing the ability to inhibit the activity of starch digestive enzymes and the absorption of glucose by the gut mucosa, respectively. By combining these extracts with a starch based meal we hope to induce enough glucose malabsorption in the proximal SI to activate the ileal brake. However, efficacy of these blockers singularly or in combination has not yet been assessed in a human study population.

Interventions

This will be a randomised, placebo controlled, double-blind, 5-condition cross-over single day study with a 2 MJ high carbohydrate (CHO) breakfast meal, comprised of 185 g of white toast bread, followed 3 hours later by a lunch meal which is consumed ad libitum until the participant is comfortably full. The 5 intervention arms are: 1. 2MJ carbohydrate breakfast + Placebo in acid –resistant capsule given 60 minutes prior to breakfast (negative control) 2. 2MJ carbohydrate breakfast + Acarbose, 50

This will be a randomised, placebo controlled, double-blind, 5-condition cross-over single day study with a 2 MJ high carbohydrate (CHO) breakfast meal, comprised of 185 g of white toast bread, followed 3 hours later by a lunch meal which is consumed ad libitum until the participant is comfortably full. The 5 intervention arms are: 1. 2MJ carbohydrate breakfast + Placebo in acid –resistant capsule given 60 minutes prior to breakfast (negative control) 2. 2MJ carbohydrate breakfast + Acarbose, 50 mg, in acid –resistant capsule given 60 minutes prior to breakfast (positive control) 3. 2MJ carbohydrate breakfast + grape seed extract (1500 mg, in acid –resistant capsule given 60 minutes prior to breakfast) 4. 2MJ carbohydrate breakfast + onion skin extract (1500 mg, in acid –resistant capsule given 60 minutes prior to breakfast) 5. 2MJ carbohydrate breakfast + grape seed extract (750 mg)/onion skin extract (750 mg) synergy in acid –resistant capsule given 60 minutes prior to breakfast Participants will arrive at Plant and Food Research Ltd in the fasted state at 0800h. Treatments will be provided at 0830h in acid-resistant capsules to ensure delivery of extracts to the small intestine avoiding any potential loss of activity in the stomach. Participants will be provided a 2MJ carbohydrate breakfast at 0930h which they must consume in 15 minutes. Capillary blood glucose concentrations will be monitored via finger prick at 0830h (t= -60), 0930h (t=0) and at 30 minute intervals for the following 3 hours (1000h, 1030h, 1100h, 1130h, 1200h and 1230h) and 60 minute intervals for the following 2 hours (1330h and 1430h). Throughout the day participants will rate hunger, fullness and other appetite-related sensations, including satisfaction, current thoughts of food (TOF), energy level, thirst and nausea using visual analogue scales (VAS). An ad libitum lunch will be served at 1230h (t=180). For the measurement of energy and macronutrient intake, foods will be weighed before and after each meal. The study day finishes at 1500h. There will be a minimum washout period of 3 days in between treatments.

Sponsors

Plant and Food Research Institute Ltd
Lead SponsorGovernment body

Study design

Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
Male
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

Inclusion Criteria -Male -Age 18-65 years -Non-obese, as defined by BMI 18-29kg/m2 -Healthy, as ascertained by self-report

Exclusion criteria

Exclusion Criteria -Obese (BMI > 29kg/m2) -Any medical conditions or medications known to affect appetite -related parameters, including depression -Participation in an active diet program and/or loss/gain of >10% body weight within the last 6 months -Smoker or ex-smoker who quit within the last 6 months -Hypersensitivities or allergies to any foods or ingredients included in the study -Dislike and/or unwilling to consume items listed as study foods -Unwilling/unable to comply with study protocol -Participating in another clinical intervention trial

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026